In a recent letter to Congress, the Drug Enforcement Administration (DEA) reaffirms its “final authority” over any cannabis reclassification decisions, regardless of recommendations from the Department of Health and Human Services (HHS).
As stakeholders anxiously await the outcome, the complex interplay between federal agencies, lawmakers, and public opinion is evident.
To reclassify or not to reclassify cannabis
In 2022, the Biden administration launched a review of federal cannabis policies. Last year, the US Department of Health and Human Services (HHS) officially recommended that cannabis be moved from Schedule I to Schedule III of the List of Narcotic Drugs. The Annexes make it possible to control substances according to their dangerousness, Annex I being the most restrictive and not recognizing any medical use while presenting a high potential for abuse.
Once HHS makes its recommendation last August, “the DEA will conduct its own review,” said the letter, sent last month.
“The DEA has final authority to classify, reclassify, or downgrade a drug under the Controlled Substances Act, after reviewing relevant statutory and regulatory criteria and the Department's scientific and medical evaluation. of Health and Human Services (HHS),” the document reads.
This clarification sparked frustration among lawmakers, including Senator Earl Blumenauer, who co-chairs the Congressional Cannabis Caucus. He and 30 other bipartisan lawmakers are urging the DEA to consider the “merits” of cannabis legalization during the review.
The DEA's response, however, provides little guidance on these concerns, maintaining a procedural approach and failing to address key arguments made by lawmakers.
Lack of transparency from HHS
HHS's recommendation to move cannabis from Schedule I to Schedule III, based on scientific evaluation, initiated the current review process. However, the details of this recommendation remain shrouded in secrecy, with hundreds of pages of explanations sent to the DEA available only in heavily redacted form.
This lack of transparency prevents stakeholders from fully understanding the reasoning behind HHS's recommendation, further complicating the decision-making process.
While a coalition of six US governors urged the Biden administration to reclassify cannabis before the end of the previous year, 29 former US attorneys came out against such a move, calling for the administration to keep cannabis in Appendix I. Six former DEA chiefs and five former White House czars also expressed opposition to the HHS recommendation.
The outcome of the DEA review will have profound implications for cannabis policy reform in the United States. Advocates and lawmakers continue to call for a comprehensive approach, urging the DEA to move beyond Schedule III and consider full declassification, namely removing cannabis from the Narcotic Drug List and decriminalizing it at the federal level. .
Shifting public opinion, reflected in a Gallup poll where seven in ten Americans support a change in cannabis policy, adds weight to the argument for a more progressive stance on state cannabis regulation. -United.
